Clinical trial
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
NCT00122226 · Amsterdam UMC, location VUmc, Other · Unknown status
Key facts
| NCT number | NCT00122226 |
|---|---|
| Title | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) |
| Official title | MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) |
| Lead sponsor | Amsterdam UMC, location VUmc, Other |
| Collaborators | Abbott Industry Boehringer Ingelheim |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | HIV Infections, HIV-Associated Lipodystrophy Syndrome |
| Intervention type | Drug |
| Interventions | Lopinavir/ritonavir + zidovudine + lamivudine, Lopinavir/ritonavir + nevirapine |
| Enrollment | 50 |
| Start date | Jan 1, 2003 |
| Completion | Jul 1, 2008 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 25, 2006 |
| Countries | Finland, Netherlands, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: